以色列全国糖尿病登记:成人糖尿病患者盲症3年发病率及危险因素
基于以色列全国糖尿病登记与盲症认证数据库交叉链接的队列研究,估算2012年登记糖尿病患者2013-2015年盲症3年发病率为31.0/万,糖尿病视网膜病变相关盲症为8.4/万。糖尿病患者总体盲症标准化发病比显著高于非糖尿病人群(1.39;95%CI 1.27-1.53),而年龄相关性黄斑变性、青光眼和白内障相关盲症的SMR无统计学意义。代谢控制差、胰岛素治疗、糖尿病病程长和慢性肾病与DR相关盲症相关,低社会经济地位与白内障及DR相关盲症均相关。
要点
- 糖尿病患者总体盲症3年发病率为31.0/万,DR相关盲症为8.4/万。
- 糖尿病患者总体盲症SMR为1.39(95%CI 1.27-1.53),显著高于非糖尿病人群。
- 代谢控制差、胰岛素治疗、长病程和慢性肾病与DR相关盲症相关。
核心结论
- 优化糖尿病代谢控制对预防DR相关盲症具有重要意义。
- 应探索并缩小社会经济地位相关的盲症风险差异,为所有糖尿病患者提供适当治疗以避免不必要的盲症。
研究设计与样本
- 队列研究,将2012年以色列全国糖尿病登记与全国盲症登记处的盲症认证数据库交叉链接。
- 纳入≥18岁糖尿病患者,计算2013-2015年总体及按主要病因分类的盲症发病率。
- 以非糖尿病人群为参考计算2013年标准化发病比(SMR),并使用多项逻辑模型识别与主要病因盲症发病率相关的协变量。
主要发现
- 总体盲症3年发病率为31.0/万,DR相关盲症为8.4/万。
- 糖尿病患者总体盲症SMR显著高于非糖尿病人群(1.39;95%CI 1.27-1.53)。
- ARMD、青光眼和白内障相关盲症的SMR无统计学意义。
- 代谢控制差、胰岛素治疗、糖尿病病程长和慢性肾病与DR相关盲症相关。
- 低社会经济地位与白内障及DR相关盲症均相关。
关键数值与推荐
- 盲症定义为获得官方盲症认证(较好眼视力≤3/60或视野<20度)。
临床怎么用
- 对糖尿病患者应重视优化代谢控制以降低DR相关盲症风险。
- 对代谢控制差、胰岛素治疗、长病程及合并慢性肾病者应加强DR相关盲症风险监测。
- 应关注低社会经济地位患者,减少盲症风险差异并保障适当治疗可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To estimate the 3-year incidence of blindness among diabetes patients aged ≥18 years; to compare blindness incidence rates of persons with and without diabetes; and to investigate risk factors associated with diabetic retinopathy (DR), age-related macular degeneration (ARMD), glaucoma, and cataract-related blindness. DESIGN: Cohort study. METHODS: The Israeli National Diabetes Registry for 2012 was cross-linked with the database of blindness certifications obtained from the National Registry of the Blind. Blindness was defined as the receipt of an official certificate of blindness (a visual acuity of 3/60 or worse, or a visual field loss of <20 degrees in the better eye.) Incidence rates of blindness, overall and by main cause of blindness, were calculated for the years 2013-2015. Standardized morbidity ratios (SMRs) for 2013 were calculated, using the nondiabetic population as a reference. A multinomial logistic model was used to identify covariates associated with the incidence of blindness by main cause of blindness. RESULTS: The 3-year incidence rates were 31.0 and 8.4 per 10 000 for overall and DR-related blindness, respectively. The SMR for overall blindness in people with diabetes was significantly higher than in the general nondiabetic population (1.39; 95% confidence interval: 1.27-1.53); however, the SMRs for ARMD, glaucoma, and cataract were not statistically significant. Poor metabolic control, insulin treatment, long diabetes duration, and chronic kidney disease were associated with DR-related blindness. Low socioeconomic status (SES) was associated with both cataract and DR-related blindness. CONCLUSIONS: Optimum metabolic control of diabetes is important for prevention of DR-related blindness. SES-related disparities in blindness risk should be explored and reduced by directing efforts to provide appropriate treatment for all diabetic patients in order to prevent unnecessary blindness.
引用
- Lutski M, Shohat T, Mery N, et al. Incidence and Risk Factors for Blindness in Adults With Diabetes: The Israeli National Diabetes Registry (INDR). Am J Ophthalmol. 2018. PMID: 30578785. doi:10.1016/j.ajo.2018.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。